Full Press Release Details
Correction to Company Announcement No. 13 of March 2, 2026
COMPANY ANNOUNCEMENT
COPENHAGEN, Denmark March 2, 2026 - Genmab A S (Nasdaq GMAB) - Correction In Company Announcement no. 13 2026 regarding transactions with shares and linked securities in Genmab A S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00. The correct price is DKK 1,867.50.
The Company's managerial employees and their closely associated persons have given Genmab A S power of attorney on their behalf to publish trading in Genmab shares by the Company's managerial employees and their closely associated persons.
This company announcement includes the vesting and net settlement of the restricted stock units granted to Jan van de Winkel and Anthony Pagano on February 24, 2023 (deferred RSUs as pertaining to annual bonus achievement).
Please find below a statement of such trading in shares issued by Genmab A S
| 1. | Details of the person discharging managerial responsibilities person closely associated | ||
| a) | Name | Jan van de Winkel | |
| 2. | Reason for the notification | ||
| a) | Position status | President Chief Executive Officer | |
| b) | Initial notification Amendment | Amendment to Company Announcement no. 13 of March 2, 2026 | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 1,867.50 | 567 | ||
| d) | Aggregated information - Aggregated volume - Price | 567 shares DKK 1,867.50 | |
| e) | Date of the transaction | 2026-03-02 | |
| f) | Place of the transaction | Outside the market |
Correction to Company Announcement No. 13 of March 2, 2026
| 1. | Details of the person discharging managerial responsibilities person closely associated | ||
| a) | Name | Anthony Pagano | |
| 2. | Reason for the notification | ||
| a) | Position status | Executive Vice President Chief Financial Officer | |
| b) | Initial notification Amendment | Amendment to Company Announcement no. 13 of March 2, 2026 | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 1,867.50 | 200 | ||
| d) | Aggregated information - Aggregated volume - Price | 200 shares DKK 1,867.50 | |
| e) | Date of the transaction | 2026-03-02 | |
| f) | Place of the transaction | Outside the market |
Correction to Company Announcement No. 13 of March 2, 2026
| 1. | Details of the person discharging managerial responsibilities person closely associated | ||
| a) | Name | Mijke Zachariasse | |
| 2. | Reason for the notification | ||
| a) | Position status | Member of the Board of Directors | |
| b) | Initial notification Amendment | Amendment to Company Announcement no. 13 of March 2, 2026 | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units (as employee of Genmab B.V.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 1,867.50 | 64 | ||
| d) | Aggregated information - Aggregated volume - Price | 64 shares DKK 1,867.50 | |
| e) | Date of the transaction | 2026-03-02 | |
| f) | Place of the transaction | Outside the market |
Correction to Company Announcement No. 13 of March 2, 2026
| 1. | Details of the person discharging managerial responsibilities person closely associated | ||
| a) | Name | Martin Schultz | |
| 2. | Reason for the notification | ||
| a) | Position status | Member of the Board of Directors | |
| b) | Initial notification Amendment | Amendment to Company Announcement no. 13 of March 2, 2026 | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units (as employee of Genmab A S) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 1,867.50 | 197 | ||
| d) | Aggregated information - Aggregated volume - Price | 197 shares DKK 1,867.50 | |
| e) | Date of the transaction | 2026-03-02 | |
| f) | Place of the transaction | Outside the market |
Correction to Company Announcement No. 13 of March 2, 2026
| 1. | Details of the person discharging managerial responsibilities person closely associated | ||
| a) | Name | Michael Kavanagh | |
| 2. | Reason for the notification | ||
| a) | Position status | Member of the Board of Directors | |
| b) | Initial notification Amendment | Amendment to Company Announcement no. 13 of March 2, 2026 | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Acquisition due to vesting of restricted stock units (as employee of Genmab US, Inc.) | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 1,867.50 | 305 | ||
| d) | Aggregated information - Aggregated volume - Price | 305 shares DKK 1,867.50 | |
| e) | Date of the transaction | 2026-03-02 | |
| f) | Place of the transaction | Outside the market |
Correction to Company Announcement No. 13 of March 2, 2026
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Marisol Peron, Senior Vice President, Global Communications Corporate Affairs
T +1 609 524 0065 E mmp genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T +45 3377 9558 E acn genmab.com
This Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A S and or its subsidiaries own the following trademarks Genmab the Y-shaped Genmab logo Genmab in combination with the Y-shaped Genmab logo HuMax DuoBody HexaBody DuoHexaBody , HexElect and KYSO .